Table 2.
Changes in the characteristics of the BAL cell infiltrate after prophylaxis with the intact anti-G protein MAb or F(ab′)2 form of 131-2Ga
| Phenotype | Untreated | F(ab′)2 131-2G-treated |
Intact 131-2G-treated |
||
|---|---|---|---|---|---|
| Mean no. of cells ± SE (103) | Mean no. of cells ± SE (103) | % reduction | Mean no. of cells ± SE (103) | % reduction | |
| CD3 | 6.46 ± 1.79 | 3.26 ± 0.51** | 43.47 ± 32.42 | 1.54 ± 0.51*** | 74.85 ± 8.60 |
| CD4 | 1.60 ± 0.46 | 0.65 ± 0.07** | 55.25 ± 8.23 | 0.29 ± 0.09*** | 78.79 ± 5.44 |
| CD8 | 1.66 ± 0.72 | 0.54 ± 0.04** | 59.95 ± 8.48 | 0.29 ± 0.12 | 77.70 ± 7.40 |
| B cell | 12.97 ± 5.16 | 2.18 ± 0.20*** | 81.63 ± 7.50 | 3.91 ± 0.77*** | 64.32 ± 19.01 |
| Macrophage | 23.36 ± 7.14 | 6.75 ± 3.90*** | 66.43 ± 10.30 | 10.96 ± 2.01*** | 53.71 ± 13.94 |
| PMN | 0.72 ± 0.23 | 0.44 ± 0.04** | 47.78 ± 14.02 | 0.30 ± 0.11*** | 62.58 ± 10.49 |
| NK | 7.33 ± 1.64 | 3.76 ± 2.22** | 52.54 ± 19.69 | 2.87 ± 0.69** | 56.38 ± 14.25 |
Mice were treated with 300 μg of the intact or F(ab′)2 form of 131-2G 2 days before RSV rA2-line19F (1 × 106 TCID50) challenge (n = 5 mice/group). Data are mean total numbers of BAL cells by subtype at day 5 p.i. per lung. Subtypes: lymphocyte gate, anti-CD3+ (17A2) and anti-CD4+ (GK1.5) CD4 T cells; lymphocyte gate, CD3+ and anti-CD8+ (53-6.7)− CD8 T cells; CD3− and anti-CD45R/B220+ (RA3-6B2)− B cells; CD3− and anti-CD11b+ (M1/70)− macrophages, dendritic cells, and monocytes; CD3− and anti-mouse Ly06G/Gr-1 (RB6-8C5)− polymorphonuclear cells (PMNs); CD3− and anti-mouse CD49b/integrin alpha 2 (DX5)− NK cells. The fold reduction is the decrease in the number of treated mice relative to the number of untreated mice for the cell type. **, P ≤ 0.05 as determined by ANOVA; ***, P ≤ 0.001, a significant decrease in the number of untreated mice compared to the number receiving the indicated treatment. Results are representative of two independent experiments for rA2-line19F challenge and F(a′)2 131-2G prophylaxis of rA2-line19F-challenged mice.